Tumour lysate particle loaded dendritic cell vaccine - Orbis Health Solutions

Drug Profile

Tumour lysate particle loaded dendritic cell vaccine - Orbis Health Solutions

Alternative Names: TL + YCWP + DC; TL-YCWP-DC; TLPLDC

Latest Information Update: 24 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Orbis Health Solutions
  • Developer Cancer Insight; Orbis Health Solutions
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Malignant melanoma
  • Phase I/II Ovarian cancer
  • Clinical Phase Unknown Solid tumours

Most Recent Events

  • 01 Apr 2017 Phase-I/II clinical trials in Ovarian cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) (Intradermal) before April 2017
  • 01 Apr 2017 Efficacy and adverse event data from a phase I/II trial in Ovarian cancer presented at the 108th Annual Meeting of the American Association for Cancer Research
  • 23 Dec 2014 Phase-II/III clinical trials in Malignant melanoma (Late-stage disease, Metastatic disease, Adjuvant therapy) in USA (Intradermal) (NCT02301611)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top